While the historical EPS growth rate for PJT Partners is 0.9%, investors should actually focus on the projected growth. The company's EPS is expected to grow 34.6% this year, crushing the industry ...

Sutro Biopharma (STRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SNOW's third-quarter fiscal 2025 results are likely to benefit from a strong portfolio despite margin pressure on rising GPU ...